文献速递瓣膜病与结构性心脏病

脂蛋白相关磷脂酶A2活性、遗传与钙化性主动脉瓣狭窄

Lipoprotein-associated phospholipase A2 activity, genetics and calcific aortic valve stenosis in humans.
PubMed 文献 · Heart · 2020-07-07

在890例心脏手术患者中,血浆Lp-PLA2活性经多变量校正后与钙化性主动脉瓣狭窄(CAVS)的存在正相关;

要点

  • Lp-PLA2活性每升高1个SD,CAVS存在风险增加(OR=1.21,95%CI 1.04–1.41)。
  • PLA2G7位点4个SNP在Meta分析中均与CAVS无显著关联。
  • Lp-PLA2或可作为心脏病患者CAVS的生物标志物,但不宜作为治疗靶点。

核心结论

  • 较高的Lp-PLA2活性与CAVS的存在显著相关,可能是心脏病患者CAVS的生物标志物。
  • 遗传关联研究结果提示Lp-PLA2不太可能是CAVS的因果危险因素或治疗靶点。

研究设计与样本

  • 在890例接受心脏手术的患者中测量血浆Lp-PLA2活性,其中476例因CAVS行主动脉瓣置换、414例为行冠状动脉旁路移植的对照。
  • 在PLA2G7位点选取4个与Lp-PLA2质量或活性相关的SNP(rs7756935、rs1421368、rs1805017、rs4498351)。

主要发现

  • 多变量校正后,Lp-PLA2活性与CAVS的存在正相关,每SD增量的OR=1.21(95%CI 1.04–1.41)。
  • Meta分析显示4个SNP均与CAVS无关:rs7756935 OR=0.99(95%CI 0.96–1.02,p=0.55);rs1421368 OR=0.97(95%CI 0.93–1.01,p=0.11);rs1805017 OR=1.00(95%CI 1.00–1.01,p=0.29);rs4498351 OR=1.00(95%CI 0.97–1.04,p=0.87)。

临床怎么用

  • 对心脏病患者,Lp-PLA2活性或可用于CAVS的风险标志物评估,但现有遗传证据不支持将其作为干预靶点。
  • 不宜基于PLA2G7基因型或Lp-PLA2通路进行CAVS的因果性干预决策。

局限性

  • 病例对照分析样本来自接受心脏手术的患者,可能存在选择偏倚,结论外推需谨慎。
  • 遗传关联采用SNP作为工具变量,结果仅反映所选取的4个SNP,不能完全排除Lp-PLA2通路的因果作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lipoprotein-associated phospholipase A2 (Lp-PLA2) activity has been shown to predict calcific aortic valve stenosis (CAVS) outcomes. Our objective was to test the association between plasma Lp-PLA2 activity and genetically elevated Lp-PLA2 mass/activity with CAVS in humans. METHODS AND RESULTS: Lp-PLA2 activity was measured in 890 patients undergoing cardiac surgery, including 476 patients undergoing aortic valve replacement for CAVS and 414 control patients undergoing coronary artery bypass grafting. After multivariable adjustment, Lp-PLA2 activity was positively associated with the presence of CAVS (OR=1.21 (95% CI 1.04 to 1.41) per SD increment). We selected four single nucleotide polymorphisms (SNPs) at the PLA2G7 locus associated with either Lp-PLA2 mass or activity (rs7756935, rs1421368, rs1805017 and rs4498351). Genetic association studies were performed in eight cohorts: Quebec-CAVS (1009 cases/1017 controls), UK Biobank (1350 cases/349 043 controls), European Prospective Investigation into Cancer and Nutrition-Norfolk (504 cases/20 307 controls), Genetic Epidemiology Research on Aging (3469 cases/51 723 controls), Malmö Diet and Cancer Study (682 cases/5963 controls) and three French cohorts (3123 cases/6532 controls), totalling 10 137 CAVS cases and 434 585 controls. A fixed-effect meta-analysis using the inverse-variance weighted method revealed that none of the four SNPs was associated with CAVS (OR=0.99 (95% CI 0.96 to 1.02, p=0.55) for rs7756935, 0.97 (95% CI 0.93 to 1.01, p=0.11) for rs1421368, 1.00 (95% CI 1.00 to 1.01, p=0.29) for rs1805017, and 1.00 (95% CI 0.97 to 1.04, p=0.87) for rs4498351). CONCLUSIONS: Higher Lp-PLA2 activity is significantly associated with the presence of CAVS and might represent a biomarker of CAVS in patients with heart disease. Results of our genetic association study suggest that Lp-PLA2 is however unlikely to represent a causal risk factor or therapeutic target for CAVS.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Perrot N, Thériault S, Rigade S, et al. Lipoprotein-associated phospholipase A2 activity, genetics and calcific aortic valve stenosis in humans. Heart. 2020. PMID: 32636298. doi:10.1136/heartjnl-2020-316722

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。